Get the Stockscreener App
66.20
0.99%
-0.6197
Hologic Inc stock is traded at $66.20, with a volume of 651.63K.
It is down -0.99% in the last 24 hours and up +1.27% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$66.82
Open:
$66.35
24h Volume:
651.63K
Relative Volume:
0.21
Market Cap:
$14.75B
Revenue:
$4.03B
Net Income/Loss:
$556.70M
P/E Ratio:
27.93
EPS:
2.37
Net Cash Flow:
$970.10M
1W Performance:
-0.51%
1M Performance:
+1.27%
6M Performance:
-8.29%
1Y Performance:
-20.48%
1-Day Range:
$65.35
$67.01
1-Week Range:
$64.78
$67.52
52-Week Range:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
66.17 | 14.48B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
482.34 | 179.42B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
175.41 | 52.03B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.17 | 44.11B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
277.98 | 40.68B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
236.54 | 17.92B | 2.90B | 467.20M | 306.90M | 6.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
What makes Hologic Inc. stock price move sharplyFree Stock Alerts For Every Investor - jammulinksnews.com
What are analysts’ price targets for Hologic Inc. in the next 12 monthsReal Time Ideas With Low Risk - jammulinksnews.com
Stock Analysis | Hologic OutlookA Closer Look at Mixed Signals and Market Trends - AInvest
Hologic 2025 Q3 Earnings Beats Expectations as Net Income Grows 0.2% - AInvest
Hologic, Inc. shares fall 1.53% after-hours following Morgan Stanley's price target adjustment to $69. - AInvest
Mizuho raises Hologic stock price target to $75 on strong quarterly results - Investing.com Canada
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down - Yahoo Finance
Hologic revenue increases 1.2% to USD 1,023.8M in Q2 2025 - Medical Buyer
HOLOGIC INC SEC 10-Q Report - TradingView
Hologic Inc (HOLX) Q3 2025 Earnings Call Highlights: Surpassing Expectations Amidst Challenges By GuruFocus - Investing.com Canada
Hologic (HOLX) Q3 Revenue Beats 1% - The Globe and Mail
Hologic Inc (HOLX) Q3 2025 Earnings Call Highlights: Surpassing Expectations Amidst Challenges - Yahoo.co
What markets is Hologic Inc. expanding into Is KMDA stock a good long term investment optionAdvanced Screener Ideas For Fast Growth - jammulinksnews.com
Hologic Announces Financial Results for Third Quarter of Fiscal 2025 - BioSpace
Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance - TipRanks
Hologic Inc Q3 Profit Increases, Beats Estimates - Nasdaq
Hologic targets mid-single-digit organic revenue growth in 2026 as Breast Health rebounds and tariff mitigation advances - MSN
Hologic's Q3 Earnings Beat: A Strategic Turnaround in the Making? - AInvest
Hologic, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:HOLX) - Seeking Alpha
Hologic raises annual profit forecast on diagnostic and surgical demand - 1470 & 100.3 WMBD
Earnings call transcript: Hologic Q3 2025 beats earnings estimates, stock dips By Investing.com - Investing.com Nigeria
Earnings call transcript: Hologic Q3 2025 beats earnings estimates, stock dips - Investing.com Australia
Hologic Q3 2025 Earnings Call Transcript - MarketBeat
Hologic's Strategic Shift: Capitalizing on Breast Health and Surgical Growth Amid Diagnostics Downturn - AInvest
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Hologic Q2 Revenue Beats Estimates, Stock Surges - AInvest
Hologic: Fiscal Q3 Earnings Snapshot - NewsTimes
Hologic Inc (HOLX) Q3 Earnings: Non-GAAP EPS of $1.08 Beats Estimates, Revenue Surpasses $1.02 Billion - GuruFocus
Hologic Q3 2025 slides: modest growth amid mixed segment performance By Investing.com - Investing.com South Africa
Hologic Q3 2025 slides: modest growth amid mixed segment performance - Investing.com Australia
Hologic earnings beat by $0.03, revenue topped estimates - Investing.com Australia
Hologic shares jump 7% as Q3 earnings and guidance top expectations - Investing.com India
Hologic Reports Q3 Earnings: EPS Beats Expectations, Revenue Tops Estimates - AInvest
Hologic’s (NASDAQ:HOLX) Q2 Sales Beat Estimates, Stock Soars - TradingView
Breast Biopsy Marker Market Set to Hit US$ 1.4 Billion by 2032 | Key - openPR.com
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver? - MSN
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
Does Hologic’s (HOLX) Debt Refinancing Signal a Shift in Financial Strategy? - simplywall.st
Gynecological Devices Market Set to Witness Significant Growth - openPR.com
Cancer Biopsy Market Set to Witness Significant Growth - openPR.com
Short Term Charts Align With Long Term Uptrend in Hologic Inc.Smart Trade Plans With Risk Protection Explained - metal.it
Hologic Inc. Quarterly Earnings Preview: Flat Revenue and Analyst ExpectationsNews and Statistics - IndexBox
Herpes Markers Testing Market Outlook 2024 to 2034: Growth - openPR.com
Human Papilloma Virus Testing Market Research Report - GlobeNewswire
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Hologic Inc. stock outperforms competitors despite losses on the day - MarketWatch
Is it the right time to buy Hologic Inc. stockSmart Portfolio Growth Plan That Work - jammulinksnews.com
Problems With BioZorb Tissue Markers Not Adequately Disclosed by Manufacturer: Lawsuit - AboutLawsuits.com
What are the technical indicators suggesting about Hologic Inc.Exceptional earning trajectories - jammulinksnews.com
Does Hologic Inc. stock perform well during market downturnsFree Capital Allocation Plans - jammulinksnews.com
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):